Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,623 matching trials from the live ClinicalTrials.gov search.
Filters: Jacksonville, Florida Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752
View directory record Official record
Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
CBP-201, placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

SB-480848 In Subjects With Coronary Heart Disease

NCT00269048
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-480848, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 7:42 PM EDT
Active, not recruiting Not applicable Interventional

Venous Sinus Stenting With the River Stent in IIH

NCT03556085
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous sinus stenting (Serenity River)
Device
Lead sponsor
Serenity Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Buffalo, New York • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

NCT00206284
View directory record Official record
Conditions
GERD Without Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

NCT00917852
View directory record Official record
Conditions
Thoracic Injuries
Interventions
Gore Conformable TAG Thoracic Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 30, 2026, 7:42 PM EDT
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 30, 2026, 7:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

High Risk Screening Breast MR Using a Rapid Imaging Exam

NCT00588614
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 75 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 30, 2026, 7:42 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084
View directory record Official record
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Estetrol, Placebo
Drug · Other
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 7:42 PM EDT
Recruiting Phase 2 Interventional

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT07406633
View directory record Official record
Conditions
GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour, Gastrointestinal Tumors
Interventions
KQB198, Imatinib (Gleevec)
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

NCT00650455
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
valdecoxib, naproxen, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
52
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 30, 2026, 7:42 PM EDT
Completed No phase listed Observational

Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia

NCT00493935
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT03489525
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 30, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Renal AL Amyloid Involvement and NEOD001

NCT03168906
View directory record Official record
Conditions
Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01478048
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
42
States / cities
Corona, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 30, 2026, 7:42 PM EDT
Active, not recruiting Not applicable Interventional

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT05232838
View directory record Official record
Conditions
Hydrocephalus, Normal Pressure, Hydrocephalus
Interventions
eShunt Implant
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Jacksonville, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional

Effect of Medically-tailored Meal Delivery Service on Changes in Hemoglobin A1c (HbA1c) in Patients With Diabetes

NCT04523155
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Medically tailored meals
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 30, 2026, 7:42 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts

NCT03297736
View directory record Official record
Conditions
Middle Ear Disease
Interventions
3D CAD/CAM autograft prosthesis, Control device
Device
Lead sponsor
Nitinetics LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 7:42 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 30, 2026, 7:42 PM EDT